<DOC>
	<DOCNO>NCT02634489</DOCNO>
	<brief_summary>A study compare pharmacokinetics tamsulosin HCl solifenacin succinate co-administration single entity tablet combination tablet EC905 steady state condition three dose strength .</brief_summary>
	<brief_title>EC905 Pharmacokinetic Profile Study</brief_title>
	<detailed_description>There 3 dose cohort 15 subject . In Period 1 , subject randomize either receive multiple dos tamsulosin HCl solifenacin succinate single entity tablet , combination tablet EC905 . The alternate treatment provide Period 2 . The cohort balance period effect first-order carry effect .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Body Mass Index 18.5 30.0 kg/m2 . Known suspected hypersensitivity tamsulosin HCl , solifenacin succinate , EC905 component formulation use . Any liver function test upper limit normal repeat measurement . Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug ( exclude nonactive hay fever ) . Subject risk urinary retention base medical history . A plan cataract surgery within 30 day completion study . Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test . Abnormal pulse rate and/or blood pressure measurement prestudy visit follow : pulse rate &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 160 mmHg ; mean diastolic blood pressure &gt; 100 mmHg ( blood pressure measurement take triplicate subject rest supine position 5 min ; pulse measure automatically ) . A marked baseline prolongation QT/QTc interval repeat measurement 450 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) . Use prescribed OTC ( overthe counter ) drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) . Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit . Any use drug abuse within 3 month prior admission Clinical Unit . History smoke 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission Clinical Unit . History drink 21 unit alcohol per week ( 1 unit = 270 cc beer 40 cc spirit 1 glass wine ) within 3 month prior admission Clinical Unit . Donation blood blood product within 3 month prior admission Clinical Unit . Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 . Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study , provide clinical study entail biological compound long terminal halflife . An exception ( partly ) participation Astellas study 905CL071 , provide washout least 12 day consider prior reenrolment . Employee Astellas Group CRO involve study .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Bladder outlet obstruction</keyword>
	<keyword>Overactive bladder</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Omnic OCAS®</keyword>
	<keyword>Vesicare®</keyword>
	<keyword>Tamsulosin hydrochloride</keyword>
	<keyword>Solifenacin succinate</keyword>
</DOC>